PharmaShots | Incisive News in 3 Shots

Subscribe Now

ALK+approval

Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC

Takeda's Alunbrig (brigatinib) Receives MHLW's Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC

January 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us